NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Orexigen Therapeutics, Inc. (NASDAQ:OREX) resulting from allegations that Orexigen may have issued materially misleading business information to the investing public.
On March 5, 2015, Forbes.com published a report quoting an FDA official who stated that the Company’s recent interim study results regarding their Contrave drug are extremely unreliable. On this news, shares of Orexigen fell $1.18 per share or over 14% from its previous closing price to $6.83 per share on March 6, 2015, damaging investors.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Orexigen investors. If you purchased shares of Orexigen before March 6, 2015, please visit the website at http://rosenlegal.com/cases-535.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.